Keytruda pembrolizumab: Phase II data

Top-line data from 6 patients with recurrent GBM in an open-label, U.S. Phase II trial showed that

Read the full 177 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE